Growth in Launch Products
Launch products grew 5.3% at constant exchange rate (CER), with expectations for higher growth in the second half of the fiscal year.
Pipeline Advancements
Positive Phase III studies for rusfertide and oveporexton, and expected Phase III data for zasocitinib in psoriasis by the end of the calendar year.
Innovent Biologics Partnership
Strategic partnership with Innovent Biologics to expand oncology pipeline with differentiated assets like IBI363 and IBI343.
Oveporexton's Potential
Oveporexton demonstrates significant improvement in narcolepsy type 1 symptoms and is on track for U.S. filing later in the year.
Strong Cash Flow
Adjusted free cash flow of JPY 525.4 billion, including improvements in working capital.